# Can ARA-290 improve wound healing in diabetic conditions?

Canonical source: https://retacompare.com/research/can-ara-290-improve-wound-healing-in-diabetic-conditions

Peptide Longevity Q&A · 2018-02-01


    Research indicates that ARA-290, also known as cibinetide, significantly improves wound healing in diabetic mice by activating the innate repair receptor. This activation enhances key factors associated with tissue repair, including vascular endothelial growth factor (VEGF) and nitric oxide pathways.

 What the research shows

The study investigated the effects of ARA-290 (cibinetide) on wound healing in a preclinical model involving genetically diabetic mice (db + /db +). The researchers administered cibinetide at a dosage of 30 µg/kg subcutaneously, comparing the outcomes to a vehicle control. The evaluation included measuring various biological markers and assessing wound healing parameters over a period of 14 days post-injury. Key metrics included vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho-eNOS (p-eNOS), and nitrite/nitrate content, alongside histological changes, angiogenesis, scar strength, and time to complete wound closure.

 Why it matters for longevity

Wound healing is a critical aspect of overall health, particularly in aging populations and individuals with diabetes, where impaired healing can lead to severe complications. The activation of the innate repair receptor by ARA-290 suggests a potential therapeutic approach to enhance tissue repair mechanisms. Improved wound healing can contribute to better health outcomes and quality of life, especially in older adults who may experience slower recovery rates. By addressing the underlying mechanisms of impaired healing, ARA-290 may play a role in promoting longevity through enhanced tissue regeneration and repair.

 Key findings at a glance

ARA-290 improved wound healing in diabetic mice compared to vehicle control.

Activation of the innate repair receptor (IRR) was a key mechanism of action.

Significant improvements were noted in VEGF levels and nitric oxide pathways.

Diabetic mice treated with ARA-290 showed enhanced angiogenesis and re-epithelization.

The study measured outcomes over a 14-day period post-injury.

 How ARA-290 works (background)

ARA-290, or cibinetide, functions as an agonist for the innate repair receptor (IRR), which plays a crucial role in tissue protection and repair. By activating this receptor, ARA-290 enhances the biological processes involved in wound healing, including angiogenesis (the formation of new blood vessels), and the production of growth factors such as VEGF. The receptor's activation leads to improved cellular signaling pathways that are essential for effective tissue regeneration, particularly in the context of diabetes, where these processes are often impaired.

 Safety, caveats, and what we don't yet know

While the findings from this study are promising, it is important to note that the research was conducted in a specific animal model. The implications for human health and safety remain to be fully established. Further studies are needed to evaluate the long-term effects of ARA-290 and its efficacy in diverse populations, including those with varying degrees of diabetes and other comorbidities. Additionally, the mechanisms of action in human tissues may differ from those observed in mice, warranting further investigation.

 Bottom line

ARA-290 shows potential for improving wound healing in diabetic conditions through the activation of the innate repair receptor, which enhances critical factors involved in tissue repair.

 Related questions

 Does ARA-290 have potential for treating other diabetic complications?

Research is ongoing to determine the broader applications of ARA-290 in managing various diabetic complications beyond wound healing, including its effects on neuropathy and cardiovascular health.

 Can ARA-290 be used for age-related tissue repair?

While current studies focus on diabetic wound healing, the mechanisms by which ARA-290 activates tissue repair may also have implications for age-related tissue regeneration, warranting further research.

 What are the potential side effects of ARA-290?

As with any therapeutic agent, understanding the safety profile of ARA-290 is crucial. Ongoing studies will help clarify any potential side effects and contraindications associated with its use.

 Source: PubMed · Biochim Biophys Acta Mol Basis Dis · published 2018-02-01.

## Sources

- PubMed · Biochim Biophys Acta Mol Basis Dis: https://pubmed.ncbi.nlm.nih.gov/29223734/